In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany.
Acinetobacter baumannii
Carbapenemase
Cefiderocol
ESBL
Enterobacterales
Pseudomonas aeruginosa
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
28
04
2020
revised:
20
07
2020
accepted:
29
07
2020
pubmed:
8
8
2020
medline:
28
5
2021
entrez:
8
8
2020
Statut:
ppublish
Résumé
Cefiderocol (CID), also known as S-649266, a novel siderophore cephalosporin, possesses potent activity against multidrug-resistant aerobic Gram-negative bacteria (GNB). This study aimed to determine the in vitro activity of CID against two different sets of GNB: i) a random sample of 213 clinical isolates, including 17 extended-spectrum beta-lactamase (ESBL) producers, obtained from intensive care unit patients with nosocomial infections collected during a multicentre surveillance study (set I); and ii) a group of 59 challenge GNB producing various types of carbapenemases (CP; set II). Minimum inhibitory concentrations (MICs) were determined using the microdilution method according to the standard ISO 20776-1. Iron-depleted medium was used for testing CID. CID inhibited 97.2% of set I isolates at the EUCAST susceptibility breakpoint of ≤ 2 mg/L. The concentrations of CID inhibiting 50% and 90% (MIC CID showed potent activity against Acinetobacter baumannii, Enterobacterales and Pseudomonas aeruginosa, including CP-producing isolates. Overall, CID inhibited 259 of 272 (95.2%) GNB at ≤ 2 mg/L.
Identifiants
pubmed: 32758648
pii: S0924-8579(20)30311-3
doi: 10.1016/j.ijantimicag.2020.106128
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
106128Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.